← Oncology Approval Tracker

FDA DECISION ·

Scemblix

asciminib · Novartis

FDA approvalNew therapyChronic myeloid leukemia
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

Adults with Philadelphia chromosome-positive chronic phase chronic myeloid leukemia and the T315I mutation.

LAMPGEN ANALYSIS

Why it matters

The same-day regular approval addressed a mutation-defined chronic-phase population.

What research teams should watch

Capture the T315I result and confirm the indication-specific dosing in the historical label.

PRIMARY RECORDS

Sources